A Dark Vector Cognition product

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

78K characters. Original on sec.gov ·

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The 23 tables in Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

The following MD&A is intended to assist the reader in understanding Amgen’s business. MD&A is provided as a supplement to, and should be read in conjunction with, the consolidated financial statements and accompanying notes of our Annual Report on Form 10-K for the year ended December 31, 2025, and the condensed consolidated financial statements and accompanying notes of this Quarterly Report on Form 10-Q and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026. Our results of operations discussed in MD&A are presented in conformity with GAAP. Amgen operates in one operating segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.

Forward-looking statements

This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management’s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases, written statements or our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as “expect,” “anticipate,” “outlook,” “could,” “target,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “should,” “may,” “assume” and “continue” as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance, and they involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Item 1A. Risk Factors in Part II herein and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2025, and in Part II, Item 1A. Risk Factors of our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026. We have based our forward-looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, EPS, liquidity and capital resources, trends, planned dividends, stock repurchases, and collaborations. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.

Overview

Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies. Our robust pipeline includes potential first-in-class medicines at all stages of development.

Our principal products are Repatha, Prolia, EVENITY, TEPEZZA, ENBREL, Otezla, BLINCYTO, TEZSPIRE, Nplate, KRYSTEXXA, XGEVA, UPLIZNA, Aranesp, KYPROLIS, Vectibix and IMDELLTRA/IMDYLLTRA. We also market a number of other products, including but not limited to PAVBLU, Neulasta, AMJEVITA/AMGEVITA, MVASI, TAVNEOS, LUMAKRAS/LUMYKRAS, Parsabiv, Aimovig, PROCYSBI and WEZLANA/WEZENLA.

Macroeconomic and other challenges

Uncertain macroeconomic conditions, including the risk of inflation, fluctuating interest rates and financial system instability, together with rising healthcare costs, evolving tariffs and trade protection measures, and geopolitical conflict continue to pose challenges to our business. The geopolitical conflict has increased volatility in the energy and transportation markets and disrupted global supply chains. Additionally, with public and private healthcare-provider focus, the industry continues to be subject to cost containment measures and significant pricing pressures, resulting in net price declines.

Moreover, provisions of the IRA, as well as the expanded utilization of the 340B Program from broadened application of 340B discounts, have negatively affected, and are likely to continue to negatively affect, our business. For example, CMS has selected ENBREL and Otezla for Medicare price setting beginning in 2026 and 2027, respectively. In addition to the IRA, other recent and proposed U.S. policy actions focus on drug pricing, including the Most-Favored-Nation Prescription Drug Pricing Executive Order (MFN EO) and the July MFN Letter that was delivered to a number of pharmaceutical companies, including Amgen. In December 2025, we announced that we are taking actions that satisfy the components outlined in the July MFN

Letter, including the Administration’s MFN pricing requests. We also announced the expansion of our direct-to-patient program. As part of the Administration’s MFN pricing initiative, CMS also announced the GENEROUS Model, under which we and other participating manufacturers will provide additional supplemental rebates for certain drugs to participating state Medicaid programs designed to align Medicaid net prices with prices paid in select other countries for drugs covered under the model. In September 2026, CMS announced that all 50 states, the District of Columbia and the U.S. territory of Puerto Rico had applied to participate in the GENEROUS Model. While these developments reflect ongoing engagement on pricing policy, the ultimate effects on our pricing, reimbursement, net sales and profitability remain uncertain in light of such evolving regulatory and policy expectations. See Part II, Item 1A. Risk Factors*—Changing U.S. federal coverage and reimbursement policies and practices have affected, and are likely to continue to affect, access to, pricing of, and sales of our products,* of this Quarterly Report on Form 10-Q for further discussion.

Numerous tariffs and trade protection measures have been proposed, and in a number of cases, implemented by the United States and other countries. Further, there have been previous proposals for sector-specific tariffs on our industry. In April 2026, the Administration issued a proclamation imposing Section 232 tariffs on certain patented pharmaceuticals and associated active pharmaceutical ingredients. However, in December 2025, in recognition of our capital investments in U.S. manufacturing, we received relief from Section 232 tariffs for approximately the next three years from that date. Given the many uncertainties and variables, tariffs and trade protection measures may adversely affect our business and results of operations.

Finally, wholesale and end-user buying patterns can affect our product sales. These buying patterns can cause fluctuations in quarterly product sales, but have generally not been significant to date when comparing full-year product performance to the prior year. For additional discussion of these and other risks, see Part II, Item 1A. Risk Factors, of this Quarterly Report on Form 10-Q.

Significant developments

The following is a summary of select significant developments affecting our business that occurred since the filing of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. For additional developments, see our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026.

Products/pipeline

TEZSPIRE

In August 2026, we and our collaboration partner AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE in patients living with eosinophilic esophagitis (EoE). TEZSPIRE demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52. The co-primary endpoints were histologic remission and the frequency and severity of dysphagia (difficulty swallowing). The safety profile of TEZSPIRE was generally consistent with its approved indications. Additionally, detailed results were presented in October 2026 at international medical congresses.

Repatha

In August 2026, the European Commission approved an expanded indication for the use of Repatha in adults with established or at high risk for atherosclerotic cardiovascular disease (ASCVD) to reduce cardiovascular (CV) risk by lowering low-density lipoprotein cholesterol (LDL-C) levels, as an adjunct to correction of other risk factors, based on results from the Phase 3 VESALIUS-CV trial.

IMDELLTRA/IMDYLLTRA

In September 2026, we announced results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA/IMDYLLTRA in combination with AstraZeneca’s IMFINZI® (durvalumab) compared to IMFINZI alone. This study tested IMDELLTRA/IMDYLLTRA as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose disease had not progressed following initial treatment with IMFINZI, platinum-based chemotherapy and etoposide. The study also demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and objective response rate (ORR) among patients treated with IMDELLTRA/IMDYLLTRA in combination with IMFINZI. Overall, the safety profile of IMDELLTRA/IMDYLLTRA in combination with IMFINZI was consistent with the known safety profiles of the individual medicines. No new or unexpected safety signals were identified in DeLLphi-305. Additionally, detailed results were presented in October 2026 at an international medical congress.

Dazodalibep

In September 2026, we announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren’s disease and moderate-to-severe systemic disease activity. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement at week 48, as measured by the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI). Improvements in ESSDAI were observed as early as week 4 with treatment with dazodalibep, which were sustained through week 48 of the study. The most common adverse events (>/= 5% incidence, reported at a higher rate in dazodalibep compared with placebo) were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions, and were generally mild to moderate in nature. Discontinuations due to adverse events occurred at a low rate and were balanced across treatment groups. No imbalance in the incidence of thromboembolic events or opportunistic infections was observed across treatment arms. Additionally, in October 2026 we released further detail of these results.

ABP 206

In September 2026, we announced submission of our Biologics License Application and its acceptance for review by the FDA for ABP 206, our biosimilar candidate to OPDIVO® (nivolumab).

ABP 234

In September 2026, we announced completion of the primary analysis of a pharmacokinetic/comparative clinical study of ABP 234, our biosimilar candidate to KEYTRUDA® (pembrolizumab), which met both primary and secondary endpoints.

Selected financial information

The following is an overview of our results of operations (in millions, except percentages and per-share data):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
Product sales
U.S.$7,259$6,7518%$20,022$18,7377%
ROW2,6242,38610%7,6167,0448%
Total product sales9,8839,1378%27,63825,7817%
Other revenues48242015%1,3991,10427%
Total revenues$10,365$9,5578%$29,037$26,8858%
Operating expenses$6,655$7,031(5)%$19,147$20,525(7)%
Operating income$3,710$2,52647%$9,890$6,36056%
Net income$3,864$3,21620%$8,058$6,37826%
Diluted EPS$7.08$5.9319%$14.79$11.7726%
Diluted shares5465421%5455421%

In the following discussion of changes in product sales, any reference to volume growth or decline refers to changes in purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and, in certain circumstances, end users (such as pharmacies) as may be noted.

Total product sales increased 8% for the three months ended September 30, 2026, driven by volume growth. Total product sales increased 7% for the nine months ended September 30, 2026, driven by volume growth of 10%, partially offset by lower net selling price.

For the three months ended September 30, 2026, U.S. volume grew 8% and ROW volume grew 16%, driven by certain brands, including Repatha, UPLIZNA, EVENITY, IMDELLTRA/IMDYLLTRA, TEZSPIRE and PAVBLU.

For the nine months ended September 30, 2026, U.S. volume grew 8% and ROW volume grew 12%, driven by certain brands, including Repatha, UPLIZNA, EVENITY, IMDELLTRA/IMDYLLTRA, PAVBLU and TEZSPIRE.

Other revenues increased 15% and 27% for the three and nine months ended September 30, 2026, respectively, driven by higher royalty income and corporate partner revenue.

Operating expenses decreased 5% and 7% for the three and nine months ended September 30, 2026, respectively, reflecting lower amortization expense from acquisition-related assets and the impact of the Otezla intangible asset impairment charges recorded in 2025, partially offset by higher spend in Research and Early Pipeline, higher profit share expense and changes in our sales mix. See Note 8, Goodwill and other intangible assets, to the condensed consolidated financial statements, for additional information related to the Otezla intangible asset impairment charges recorded in 2025.

For the remainder of 2026, we expect volume growth from certain brands to be partially offset by net selling price declines.

Uncertain macroeconomic conditions, including geopolitical conflict and rising geopolitical tensions, changes in the healthcare ecosystem, and potential government policy actions, including MFN pricing or similar drug pricing reforms and tariffs or trade protection measures, have the potential to introduce variability into product sales. Furthermore, product sales continue to be impacted by actions from governments and other entities to address macroeconomic challenges; provisions of the IRA; expanded utilization of the 340B Program from broadened application of 340B discounts; reductions in federal Medicaid spending; and an increase in the number of people without health insurance. See Part I, Item 1. Business—Reimbursement, and Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2025; and Part II, Item 1A. Risk Factors, of our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026.

Results of operations

Product sales

Worldwide product sales were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
Repatha$1,085$79437%$2,914$2,14636%
Prolia6321,139(45)%2,1183,360(37)%
EVENITY75154139%2,0271,50135%
TEPEZZA526560(6)%1,5921,44610%
ENBREL6115805%1,5111,694(11)%
Otezla481585(18)%1,4031,640(14)%
BLINCYTO49639227%1,3831,14621%
TEZSPIRE(1)53837743%1,3671,00436%
Nplate4724573%1,3141,13915%
KRYSTEXXA41932031%1,07490519%
XGEVA288539(47)%1,0511,637(36)%
UPLIZNA451155*1,048422*
Aranesp329357(8)%9921,056(6)%
KYPROLIS330359(8)%9741,061(8)%
Vectibix33528418%96085612%
IMDELLTRA/IMDYLLTRA406178*952393*
Other products(2)1,7331,52014%4,9584,37513%
Total product sales$9,883$9,1378%$27,638$25,7817%
  • Change in excess of 100%

(1) TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.

(2) Consists of product sales of our non-principal products.

Future sales of our products will depend in part on the factors discussed below and in the following sections of this report: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Selected financial information; and (ii) Part II, Item 1A. Risk Factors, and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2025: (i) Part I, Item 1. Business—Marketing, Distribution and Selected Marketed

Products; (ii) Part I, Item 1. Business—Reimbursement; (iii) Part I, Item 1A. Risk Factors; and (iv) Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of operations—Product sales, as well as in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of operations—Product sales; and (ii) Part II, Item 1A. Risk Factors.

Repatha

Total Repatha sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
Repatha — U.S.$666$44251%$1,641$1,14643%
Repatha — ROW41935219%1,2731,00027%
Total Repatha$1,085$79437%$2,914$2,14636%

The increases in global Repatha sales for the three and nine months ended September 30, 2026 were primarily driven by volume growth.

For a discussion of litigation, including associated settlements, related to Repatha, see Part IV—Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2025; and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Prolia

Total Prolia sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
Prolia — U.S.$409$806(49)%$1,348$2,271(41)%
Prolia — ROW223333(33)%7701,089(29)%
Total Prolia$632$1,139(45)%$2,118$3,360(37)%

Global Prolia sales for the three and nine months ended September 30, 2026 decreased 45% and 37%, respectively, as multiple biosimilars have launched in the United States and ROW.

The decrease in global Prolia sales for the three months ended September 30, 2026 was driven by lower volume of 23%, with the remainder driven equally by lower net selling price and changes to estimated sales deductions.

The decrease in global Prolia sales for the nine months ended September 30, 2026 was primarily driven by lower volume of 20% and lower net selling price of 13%.

For the remainder of 2026, we expect continued sales erosion driven by increased competition, as multiple biosimilars have launched in the United States and ROW.

As disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products, our patents for RANKL antibodies, including sequences, for Prolia and XGEVA expired in February 2025 in the United States and in November 2025 in select countries in Europe.

For a discussion of litigation, including associated settlements, related to Prolia, see Part IV—Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2025; and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026.

EVENITY

Total EVENITY sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
EVENITY — U.S.$557$41734%$1,538$1,13236%
EVENITY — ROW19412456%48936933%
Total EVENITY$751$54139%$2,027$1,50135%

The increases in global EVENITY sales for the three and nine months ended September 30, 2026 were driven by volume growth.

TEPEZZA

Total TEPEZZA sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
TEPEZZA — U.S.$441$518(15)%$1,385$1,3493%
TEPEZZA — ROW8542*20797*
Total TEPEZZA$526$560(6)%$1,592$1,44610%
  • Change in excess of 100%

The decrease in global TEPEZZA sales for the three months ended September 30, 2026 was driven by lower inventory.

The increase in global TEPEZZA sales for the nine months ended September 30, 2026 was primarily driven by higher net selling price of 6% and higher inventory.

ENBREL

Total ENBREL sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
ENBREL — U.S.$605$5745%$1,493$1,675(11)%
ENBREL — Canada66—%1819(5)%
Total ENBREL$611$5805%$1,511$1,694(11)%

The increase in ENBREL sales for the three months ended September 30, 2026 was driven by favorable changes to estimated sales deductions of 15% and higher inventory of 8%, partially offset by lower net selling price of 14% reflecting the ongoing impact of U.S. Medicare Part D price setting effective in 2026 under the IRA, and lower volume.

The decrease in ENBREL sales for the nine months ended September 30, 2026 was driven by lower net selling price of 19% reflecting the ongoing impact of U.S. Medicare Part D price setting effective in 2026 under the IRA, as well as an increase in 340B Program mix, partially offset by favorable changes to estimated sales deductions.

Otezla

Total Otezla sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
Otezla — U.S.$428$473(10)%$1,211$1,328(9)%
Otezla — ROW53112(53)%192312(38)%
Total Otezla$481$585(18)%$1,403$1,640(14)%

The decrease in global Otezla sales for the three months ended September 30, 2026 was driven by lower volume of 13%, unfavorable changes to estimated sales deductions of 9% and lower net selling price of 4%, partially offset by higher inventory.

The decrease in global Otezla sales for the nine months ended September 30, 2026 was driven by lower net selling price of 10% and lower volume of 8%.

Otezla ROW sales were unfavorably impacted for the three and nine months ended September 30, 2026 by generic competition following loss of exclusivity in certain European countries during the first quarter of 2026.

In January 2025, Otezla was selected by CMS for Medicare price setting that will be applicable beginning in 2027. As a result, we expect further declines in net selling price driven by Medicare price setting beginning in 2027. See Note 8, Goodwill and other intangible assets, to the condensed consolidated financial statements, for additional information related to the Otezla intangible asset impairment charges recorded in 2025.

BLINCYTO

Total BLINCYTO sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
BLINCYTO — U.S.$269$23614%$775$779(1)%
BLINCYTO — ROW22715646%60836766%
Total BLINCYTO$496$39227%$1,383$1,14621%

The increases in global BLINCYTO sales for the three and nine months ended September 30, 2026 were primarily driven by volume growth.

TEZSPIRE

Total TEZSPIRE sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
TEZSPIRE — U.S.$538$37743%$1,367$1,00436%

The increases in TEZSPIRE sales for the three and nine months ended September 30, 2026 were driven by volume growth.

Nplate

Total Nplate sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
Nplate — U.S.$347$3334%$905$76219%
Nplate — ROW1251241%4093778%
Total Nplate$472$4573%$1,314$1,13915%

Global Nplate sales for the three months ended September 30, 2026 increased 3% and included U.S. government orders of $65 million and $90 million for the three months ended September 30, 2026 and 2025, respectively. Excluding the U.S. government orders from this comparison, global Nplate sales increased 11% for the three months ended September 30, 2026, primarily driven by volume growth.

Global Nplate sales for the nine months ended September 30, 2026 increased 15% and included U.S. government orders of $125 million and $90 million for the nine months ended September 30, 2026 and 2025, respectively. Excluding the U.S. government orders from this comparison, global Nplate sales increased 13% for the nine months ended September 30, 2026, driven by volume growth of 11% and higher net selling price.

KRYSTEXXA

Total KRYSTEXXA sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
KRYSTEXXA — U.S.$419$32031%$1,073$90519%
KRYSTEXXA — ROW——N/A1—N/A
Total KRYSTEXXA$419$32031%$1,074$90519%

N/A = not applicable

The increases in KRYSTEXXA sales for the three and nine months ended September 30, 2026 were primarily driven by higher net selling price.

XGEVA

Total XGEVA sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
XGEVA — U.S.$170$357(52)%$585$1,064(45)%
XGEVA — ROW118182(35)%466573(19)%
Total XGEVA$288$539(47)%$1,051$1,637(36)%

Global XGEVA sales for the three and nine months ended September 30, 2026 decreased 47% and 36%, respectively, as multiple biosimilars have launched in the United States and ROW.

The decreases in global XGEVA sales for the three and nine months ended September 30, 2026 were primarily driven by lower volume of 32% and 24%, respectively, and lower net selling price of 11% and 10%, respectively.

For the remainder of 2026, we expect continued sales erosion driven by increased competition, as multiple biosimilars have launched in the United States and ROW.

As disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products, our patents for RANKL antibodies, including sequences, for Prolia and XGEVA expired in February 2025 in the United States and in November 2025 in select countries in Europe.

For a discussion of litigation, including associated settlements, related to XGEVA, see Part IV—Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2025; and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026.

UPLIZNA

Total UPLIZNA sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
UPLIZNA — U.S.$352$146*$915$360*
UPLIZNA — ROW999*13362*
Total UPLIZNA$451$155*$1,048$422*
  • Change in excess of 100%

The increases in global UPLIZNA sales for the three and nine months ended September 30, 2026 were primarily driven by volume growth.

Aranesp

Total Aranesp sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
Aranesp — U.S.$95$103(8)%$266$301(12)%
Aranesp — ROW234254(8)%726755(4)%
Total Aranesp$329$357(8)%$992$1,056(6)%

The decrease in global Aranesp sales for the three months ended September 30, 2026 was primarily driven by lower volume.

The decrease in global Aranesp sales for the nine months ended September 30, 2026 was driven by lower net selling price of 3% and lower volume.

KYPROLIS

Total KYPROLIS sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
KYPROLIS — U.S.$209$225(7)%$628$673(7)%
KYPROLIS — ROW121134(10)%346388(11)%
Total KYPROLIS$330$359(8)%$974$1,061(8)%

The decreases in global KYPROLIS sales for the three and nine months ended September 30, 2026 were primarily driven by lower volume.

For a discussion of ongoing litigation related to KYPROLIS, see Part IV—Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2025; and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026.

Vectibix

Total Vectibix sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
Vectibix — U.S.$182$16212%$485$44110%
Vectibix — ROW15312225%47541514%
Total Vectibix$335$28418%$960$85612%

The increases in global Vectibix sales for the three and nine months ended September 30, 2026 were primarily driven by volume growth.

IMDELLTRA/IMDYLLTRA

Total IMDELLTRA/IMDYLLTRA sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
IMDELLTRA — U.S.$224$14456%$645$33095%
IMDYLLTRA — ROW18234*30763*
Total IMDELLTRA/IMDYLLTRA$406$178*$952$393*
  • Change in excess of 100%

The increases in global IMDELLTRA/IMDYLLTRA sales for the three and nine months ended September 30, 2026 were driven by volume growth.

Other products

Other product sales by geographic region were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
PAVBLU — U.S.$294$21239%$850$43795%
PAVBLU — ROW61*175*
Neulasta — U.S.17872*491244*
Neulasta — ROW1720(15)%4859(19)%
AMJEVITA — U.S.6416*13120*
AMGEVITA — ROW127138(8)%388403(4)%
MVASI — U.S.128156(18)%330436(24)%
MVASI — ROW4057(30)%141147(4)%
TAVNEOS — U.S.1051014%36228129%
TAVNEOS — ROW—6(100)%1226(54)%
LUMAKRAS — U.S.5557(4)%1661641%
LUMYKRAS — ROW473921%14110732%
Parsabiv — U.S.3842(10)%135143(6)%
Parsabiv — ROW44425%13512112%
Aimovig — U.S.8390(8)%232239(3)%
Aimovig — ROW6520%191619%
PROCYSBI — U.S.63622%1811744%
PROCYSBI — ROW11—%55—%
WEZLANA — U.S.8—N/A12123(90)%
WEZENLA — ROW524418%15610647%
Other — U.S.(1)3323107%872956(9)%
Other — ROW(1)4549(8)%134163(18)%
Total other products$1,733$1,52014%$4,958$4,37513%
Total U.S. — other products$1,348$1,11821%$3,762$3,21717%
Total ROW — other products385402(4)%1,1961,1583%
Total other products$1,733$1,52014%$4,958$4,37513%
  • Change in excess of 100%

N/A = not applicable


(1) Consists of product sales from KANJINTI, AVSOLA, RAVICTI, BKEMV/BEKEMV, RIABNI, EPOGEN, IMLYGIC, NEUPOGEN, ACTIMMUNE, RAYOS, QUINSAIR, BUPHENYL, Sensipar/Mimpara, DUEXIS, Corlanor and PENNSAID.

Operating expenses

Operating expenses were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
20262025Change20262025Change
Operating expenses:
Cost of sales$2,788$3,082(10)%$8,343$9,061(8)%
% of product sales28.2%33.7%30.2%35.1%
% of total revenues26.9%32.2%28.7%33.7%
Research and development$2,111$1,90011%$5,698$5,13011%
% of product sales21.4%20.8%20.6%19.9%
% of total revenues20.4%19.9%19.6%19.1%
Selling, general and administrative$1,680$1,720(2)%$5,027$5,098(1)%
% of product sales17.0%18.8%18.2%19.8%
% of total revenues16.2%18.0%17.3%19.0%
Other$76$329(77)%$79$1,236(94)%
Total operating expenses$6,655$7,031(5)%$19,147$20,525(7)%

Cost of sales

Cost of sales decreased to 26.9% of total revenues for the three months ended September 30, 2026, driven by lower amortization expense from acquisition-related assets and lower manufacturing costs, partially offset by higher profit share expense and changes in our sales mix.

Cost of sales decreased to 28.7% of total revenues for the nine months ended September 30, 2026, driven by lower amortization expense from acquisition-related assets, partially offset by higher profit share expense and changes in our sales mix.

Research and development

The increase in R&D expense for the three months ended September 30, 2026, was driven by higher spend in Research and Early Pipeline, including business development activity.

The increase in R&D expense for the nine months ended September 30, 2026, was driven by higher spend in Research and Early Pipeline, including business development activity, and Later-Stage Clinical Programs, primarily those related to MariTide.

Selling, general and administrative

The decreases in SG&A expense for the three and nine months ended September 30, 2026, were driven by lower general and administrative expenses, partially offset by higher commercial product-related expenses.

Other

Other operating expenses for the three and nine months ended September 30, 2026, included intangible asset impairment charges, and for the nine months ended September 30, 2026, also included certain items associated with legal proceedings.

Other operating expenses for the three and nine months ended September 30, 2025, included the Otezla intangible asset impairment charges of $400 million and $1.2 billion, respectively, following its selection for price setting under the IRA. See Note 8, Goodwill and other intangible assets, to the condensed consolidated financial statements.

Nonoperating expenses/income and income taxes

Nonoperating expenses/income and income taxes were as follows (dollar amounts in millions):

Three months ended September 30,Nine months ended September 30,
2026202520262025
Interest expense, net$(653)$(685)$(1,983)$(2,102)
Other income, net$1,629$2,080$1,631$3,204
Provision for income taxes$822$705$1,480$1,084
Effective tax rate17.5%18.0%15.5%14.5%

Interest expense, net

Interest expense, net, remained relatively unchanged for the three months ended September 30, 2026. Interest expense, net, decreased for the nine months ended September 30, 2026, primarily due to lower average debt outstanding.

Other income, net

Other income, net, decreased for the three and nine months ended September 30, 2026, primarily due to lower net unrealized gains on equity investments, primarily BeOne. See Note 6, Investments, to the condensed consolidated financial statements.

Income taxes

The decrease in our effective tax rate for the three months ended September 30, 2026, was primarily due to the change in earnings mix, including lower net unrealized gains on equity investments, partially offset by prior-year period net favorable items as compared to the current-year period. The increase in our effective tax rate for the nine months ended September 30, 2026, was primarily due to the prior year Otezla intangible asset impairment charges and net unfavorable items in the current-year period as compared to the prior-year period, partially offset by the change in earnings mix, including lower net unrealized gains on equity investments and lower amortization expense from acquisition-related assets.

In 2021, the OECD reached an initial agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. Select individual countries, including the United Kingdom, EU member countries and Singapore, have enacted the global minimum tax agreement that took effect starting in 2024. Singapore’s enactment of the agreement effective 2025 applies irrespective of the Company’s incentive grant. On January 5, 2026, the OECD issued administrative guidance related to the global minimum tax agreement that, when fully enacted, will exempt U.S. companies from extra territorial minimum taxes effective January 1, 2026. Countries have begun to enact, or have announced intentions to enact, the new guidance, and we continue to monitor the potential impact to our 2026 tax rate.

On July 4, 2025, OB3 was enacted in the United States. OB3 has various provisions, including the permanent extension of certain expiring provisions of the 2017 Tax Act and modifications to the international tax framework, including tax rate changes on foreign earnings. The legislation has multiple effective dates, with most provisions effective as of January 1, 2026.

In 2017, we received an RAR and a modified RAR from the IRS for the years 2010–2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations, and in 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010–2012. The Notices seek to increase our U.S. taxable income for the years 2010–2012 by an amount that would result in additional federal tax of approximately $3.6 billion, plus interest. Any additional tax that could be imposed for the years 2010–2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued and paid on our foreign earnings.

In 2020, we received an RAR and a modified RAR from the IRS for the years 2013–2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010–2012. We disagreed with the proposed adjustments and calculations, and in 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013–2015. The Notice seeks to increase our U.S. taxable income for the years 2013–2015 by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest, and asserts penalties of approximately $2.0 billion. Any additional tax that could be imposed for the years 2013–2015 would be reduced by up to approximately $2.2 billion of repatriation tax previously accrued and paid on our foreign earnings.

We firmly believe that the IRS positions set forth in the 2010–2012 and 2013–2015 Notices are without merit. We continue to contest the 2010–2012 and 2013–2015 Notices through the judicial process. The two cases were consolidated in the U.S. Tax Court in 2022. The trial began on November 4, 2024 and concluded on January 17, 2025. The parties filed opening post-trial briefs on June 13, 2025, and the Court held oral argument on July 16, 2025. The parties filed post-trial reply briefs on October 10, 2025. On March 16, 2026, the Court ordered supplemental closing briefs, which were filed on May 20, 2026. The Company expects a decision from the U.S. Tax Court no earlier than late 2026 or early 2027.

We are currently under examination by the IRS for the years 2016–2018. In April 2026, we received a draft notice of proposed adjustment (NOPA) from the IRS for years 2016–2018, which is similar to the proposed adjustments for years 2010–2015 and relates primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In May and July 2026, the IRS reissued the NOPA in substantially the same form. We have informed the IRS audit team that its methodology is inconsistent with certain positions asserted by the IRS in the Tax Court, which positions were more favorable to Amgen than those previously taken by the audit team. In September 2026, we received a draft NOPA from the IRS asserting penalties for years 2016-2018 substantially similar to those the IRS asserted for years 2013-2015. If sustained in full, these proposed adjustments and penalties could have a material impact on our financial statements. We disagree with the proposed adjustments and penalties and intend to contest them. The IRS began its audit for years 2019–2022 in the second quarter of 2026, and we believe that it may seek to continue to audit similar issues related to the allocation of income between the United States and our foreign jurisdictions. In addition, we are under examination by a number of state and foreign tax jurisdictions.

Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.

See Part I, Item 1A. Risk Factors—We could be subject to additional tax liabilities, including from an adverse outcome in our ongoing tax dispute with the IRS and other tax examinations, enactment of the OECD minimum corporate tax rate agreement and the adoption and interpretation of new tax legislation, including OB3. Such tax liabilities could adversely affect our profitability and results of operations of our Annual Report on Form 10-K for the year ended December 31, 2025 and Note 4, Income taxes, to the condensed consolidated financial statements of this Quarterly Report on Form 10-Q for further discussion.

Financial condition, liquidity and capital resources

Selected financial data were as follows (in millions):

September 30, 2026December 31, 2025
Cash and cash equivalents$13,190$9,129
Total assets$96,048$90,586
Current portion of long-term debt$2,398$4,599
Long-term debt$51,609$50,005
Stockholders’ equity$14,352$8,658

Cash and cash equivalents

Our balance of cash and cash equivalents was $13.2 billion as of September 30, 2026. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.

Capital allocation

Consistent with the objective to optimize our capital structure, we deploy our accumulated cash balances in a strategic manner and consider a number of alternatives, including investments in innovation both internally and externally (including investments that expand our portfolio of products in areas of therapeutic interest), capital expenditures, repayment of debt, payment of dividends and stock repurchases.

We intend to continue investing in our business while returning capital to stockholders through the payment of cash dividends and stock repurchases. This reflects our desire to optimize our cost of capital and our confidence in the future cash flows of our business. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, debt levels and debt service requirements, our credit rating, availability of financing on acceptable terms, changes to applicable tax laws or corporate laws, changes to our business model and periodic determination by our Board of Directors that cash dividends and/or stock repurchases are in the best interests of stockholders and are in compliance with applicable laws and the Company’s agreements. In addition, the timing and amount of stock repurchases may also be affected by our overall level of cash, stock price and blackout periods, during which we are restricted from repurchasing stock. The manner of stock repurchases may include block purchases, tender offers, accelerated share repurchases and market transactions.

In December 2025, March 2026 and July 2026, our Board of Directors declared quarterly cash dividends of $2.52 per share of common stock for the first, second and third quarters of 2026, respectively, an increase of 6% over the same periods in the prior year, which were paid in March 2026, June 2026 and September 2026, respectively. In October 2026, our Board of Directors declared a quarterly cash dividend of $2.52 per share, which will be paid in December 2026.

During the nine months ended September 30, 2026, we did not repurchase shares under our stock repurchase program. As of September 30, 2026, $6.8 billion of authorization remained available under the stock repurchase program.

As a result of stock repurchases and quarterly dividend payments, we have an accumulated deficit as of September 30, 2026 and December 31, 2025. Our accumulated deficit is not anticipated to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our expected continued profitability and strong financial position.

During the nine months ended September 30, 2026, we issued $4.0 billion of debt consisting of $1.0 billion of the 4.20% 2031 Notes, $1.75 billion of the 4.85% 2036 Notes, $500 million of the 5.50% 2046 Notes and $750 million of the 5.65% 2056 Notes. There were no debt issuances during the nine months ended September 30, 2025.

During the nine months ended September 30, 2026, we repaid $3.9 billion of debt, consisting of repayments in full of the $1.8 billion Term loan, the $1.25 billion aggregate principal amount of the 2.60% 2026 Notes and the €750 million aggregate principal amount of our 2.00% 2026 euro Notes ($833 million upon settlement of the related cross-currency swap), compared to $5.0 billion of debt repayments during the nine months ended September 30, 2025. We periodically consider the repurchase of our debt when conditions are favorable. During the nine months ended September 30, 2026 and 2025, we repurchased aggregate principal amounts of our debt of $324 million and $1.0 billion, respectively, for aggregate costs of $233 million and $683 million, respectively, which resulted in the recognition of gains on extinguishment of debt of $90 million and $264 million, respectively, recorded in Other income, net, in the Condensed Consolidated Statements of Income.

We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditure and debt service requirements, as well as our plans to pay dividends and repurchase stock, and other business initiatives we plan to strategically pursue, including acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, borrowings through commercial paper and/or syndicated credit facilities and access to other domestic and foreign debt markets and equity markets. See Part II, Item 1A. Risk Factors—Global economic conditions may negatively affect us and may magnify certain risks that affect our business, of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

In the first quarter of 2026, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities, common stock, preferred stock, warrants to purchase securities (including debt securities, common stock, preferred stock or depositary shares), rights to purchase common stock or preferred stock, securities purchase contracts, securities purchase units, and depositary shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2029. Also in the first quarter of 2026, we extended the term of our $4.0 billion syndicated, unsecured, revolving credit facility by one year to March 2029. As of September 30, 2026 and December 31, 2025, no amounts were outstanding under this facility.

Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement and term loan credit agreement include a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (consolidated earnings before interest, taxes, depreciation and amortization) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements. We were in compliance with all applicable covenants under these arrangements as of September 30, 2026.

Cash flows

Our summarized cash flow activity was as follows (in millions):

Nine months ended September 30,
20262025
Net cash provided by operating activities$10,432$8,355
Net cash used in investing activities$(1,934)$(1,250)
Net cash used in financing activities$(4,437)$(9,633)

Operating

Cash provided by operating activities has been and is expected to continue to be our primary recurring source of funds. Cash provided by operating activities during the nine months ended September 30, 2026, increased as compared to the same period in the prior year primarily due to the final $1.8 billion repatriation tax payment in the second quarter of 2025 and higher net income in the current-year period after adjustments for noncash items, partially offset by the timing of working capital items.

Investing

Cash used in investing activities during the nine months ended September 30, 2026 and 2025, was primarily due to capital expenditures of $1.8 billion and $1.2 billion, respectively, including construction costs for new plants and expansion of manufacturing capacity. We currently estimate full year 2026 investments in capital projects to be approximately $2.6 billion.

Financing

Cash used in financing activities during the nine months ended September 30, 2026, was primarily due to the repayment and extinguishment of debt of $3.9 billion and $233 million, respectively, and the payment of dividends of $4.1 billion, partially offset by $4.0 billion of net proceeds from long-term debt issuances. Cash used in financing activities during the nine months ended September 30, 2025, was primarily due to the repayment and extinguishment of debt of $5.0 billion and $683 million, respectively, and the payment of dividends of $3.8 billion. See Note 9, Financing arrangements, and Note 10, Stockholders’ equity, to the condensed consolidated financial statements for further discussion.

Critical accounting policies and estimates

The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies and estimates is presented in Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes to our critical accounting policies and estimates during the nine months ended September 30, 2026.

Recently issued accounting standards

For a discussion of recently issued accounting standards, see Note 1, Summary of significant accounting policies, to the condensed consolidated financial statements.

Previous: Item 1. FINANCIAL STATEMENTS · Next: Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK